Mono-chemotherapy with selective SETD8 inhibitors such as UNC0379, or a combination of chemotherapy using a selective SETD8 inhibitor and conventional anti-cancer drugs might be a promising strategy to improve the outcome of patients with high-risk endometrial cancer. Here, KMT5A is linked to cancer.